SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3sl5'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site

Query pattern: Residues from known binding site for annotated drug that match the hit pattern


(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID
Hit
Macromolecule
Res.
Matches
Interface HETATM RMSD Dali
Z-score
Seq.
Identity (%)
View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1DTL_A_BEPA204_1
(CARDIAC TROPONIN C)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 LEU A  96
VAL A 106
GLU A 150
LEU A 149
LEU A 146
LEU  A  96 ( 0.5A)
VAL  A 106 ( 0.6A)
GLU  A 150 ( 0.5A)
LEU  A 149 ( 0.6A)
LEU  A 146 ( 0.5A)
1.04A 1dtlA-3sl5A:
undetectable
1dtlA-3sl5A:
19.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
6 / 10 TYR A 159
HIS A 160
PHE A 340
GLN A 369
GLY A 371
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
GLY  A 371 ( 0.0A)
PHE  A 372 (-1.3A)
0.37A 1uhoA-3sl5A:
36.4
1uhoA-3sl5A:
28.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XLX_A_CIOA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 HIS A 315
LEU A 399
THR A 333
SER A 368
GLN A 369
HIS  A 315 ( 1.0A)
LEU  A 399 ( 0.6A)
THR  A 333 ( 0.8A)
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
1.31A 1xlxA-3sl5A:
51.0
1xlxA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XLX_A_CIOA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
HIS A 204
MET A 273
LEU A 319
ASN A 321
THR A 333
ILE A 336
MET A 337
SER A 368
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
HIS  A 204 ( 1.0A)
MET  A 273 (-0.0A)
LEU  A 319 ( 0.6A)
ASN  A 321 (-0.6A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.54A 1xlxA-3sl5A:
51.0
1xlxA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XLX_B_CIOB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
10 / 12 TYR A 159
HIS A 160
HIS A 204
MET A 273
ILE A 336
MET A 337
PHE A 340
MET A 357
SER A 368
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
HIS  A 204 ( 1.0A)
MET  A 273 (-0.0A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
PHE  A 372 (-1.3A)
0.74A 1xlxB-3sl5A:
51.1
1xlxB-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XLX_B_CIOB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
HIS A 204
MET A 273
THR A 333
ILE A 336
MET A 337
PHE A 340
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
HIS  A 204 ( 1.0A)
MET  A 273 (-0.0A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.54A 1xlxB-3sl5A:
51.1
1xlxB-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XMU_A_ROFA101_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
ASP A 318
LEU A 319
PRO A 322
TYR A 329
TRP A 332
ILE A 336
PHE A 340
MET A 357
SER A 368
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
PHE  A 372 (-1.3A)
0.61A 1xmuA-3sl5A:
51.4
1xmuA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XMU_A_ROFA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 5 MET A 273
ASN A 321
THR A 333
MET A 337
GLN A 369
MET  A 273 (-0.0A)
ASN  A 321 (-0.6A)
THR  A 333 ( 0.8A)
MET  A 337 ( 0.0A)
GLN  A 369 (-0.6A)
0.26A 1xmuA-3sl5A:
51.4
1xmuA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XMU_B_ROFB102_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
PRO A 322
TYR A 329
TRP A 332
ILE A 336
PHE A 340
MET A 357
SER A 368
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
0.44A 1xmuB-3sl5A:
51.1
1xmuB-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XMU_B_ROFB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 5 ASN A 321
THR A 333
MET A 337
GLN A 369
PHE A 372
ASN  A 321 (-0.6A)
THR  A 333 ( 0.8A)
MET  A 337 ( 0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.51A 1xmuB-3sl5A:
51.1
1xmuB-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOM_A_CIOA603_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
6 / 12 TYR A 159
ASP A 201
ILE A 336
MET A 337
PHE A 340
MET A 357
TYR  A 159 (-1.3A)
ASP  A 201 ( 0.5A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
1.47A 1xomA-3sl5A:
53.0
1xomA-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOM_A_CIOA603_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
ILE A 336
MET A 337
PHE A 340
MET A 357
SER A 368
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.57A 1xomA-3sl5A:
53.0
1xomA-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOM_B_CIOB601_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
LEU A 319
THR A 333
ILE A 336
MET A 337
PHE A 340
MET A 357
SER A 368
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
LEU  A 319 ( 0.6A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.59A 1xomB-3sl5A:
52.8
1xomB-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOQ_A_ROFA502_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
PRO A 322
TYR A 329
THR A 333
ILE A 336
MET A 357
SER A 368
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
0.54A 1xoqA-3sl5A:
53.5
1xoqA-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOQ_A_ROFA502_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
PRO A 322
TYR A 329
THR A 333
ILE A 336
SER A 368
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
SER  A 368 (-0.0A)
PHE  A 372 (-1.3A)
0.52A 1xoqA-3sl5A:
53.5
1xoqA-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOQ_A_ROFA502_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
3 / 3 ASN A 321
TRP A 332
GLN A 369
ASN  A 321 (-0.6A)
TRP  A 332 ( 0.5A)
GLN  A 369 (-0.6A)
0.25A 1xoqA-3sl5A:
53.5
1xoqA-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOQ_B_ROFB501_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
ASP A 318
LEU A 319
PRO A 322
TYR A 329
TRP A 332
THR A 333
ILE A 336
MET A 357
SER A 368
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
0.49A 1xoqB-3sl5A:
53.4
1xoqB-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOQ_B_ROFB501_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
ASP A 318
LEU A 319
PRO A 322
TYR A 329
TRP A 332
THR A 333
ILE A 336
SER A 368
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
SER  A 368 (-0.0A)
PHE  A 372 (-1.3A)
0.50A 1xoqB-3sl5A:
53.4
1xoqB-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOQ_B_ROFB501_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
3 / 3 MET A 273
ASN A 321
GLN A 369
MET  A 273 (-0.0A)
ASN  A 321 (-0.6A)
GLN  A 369 (-0.6A)
0.31A 1xoqB-3sl5A:
53.4
1xoqB-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOS_A_VIAA1_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
MET A 337
PHE A 340
MET A 357
GLN A 369
PHE A 372
ILE A 376
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
ILE  A 376 (-0.6A)
0.48A 1xosA-3sl5A:
51.3
1xosA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOS_A_VIAA1_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
10 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
MET A 337
PHE A 340
SER A 355
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
MET  A 337 ( 0.0A)
PHE  A 340 (-1.3A)
SER  A 355 ( 0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
1.02A 1xosA-3sl5A:
51.3
1xosA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
LEU A 319
ILE A 336
MET A 337
SER A 355
MET A 357
SER A 368
GLN A 369
PHE A 372
ILE A 376
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
LEU  A 319 ( 0.6A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
SER  A 355 ( 0.0A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
ILE  A 376 (-0.6A)
0.74A 1xotA-3sl5A:
50.9
1xotA-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
MET A 273
LEU A 319
ASN A 321
ILE A 336
MET A 337
SER A 355
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
LEU  A 319 ( 0.6A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
SER  A 355 ( 0.0A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.59A 1xotB-3sl5A:
50.9
1xotB-3sl5A:
84.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
MET A 273
LEU A 319
ASN A 321
ILE A 336
MET A 337
SER A 355
MET A 357
SER A 368
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
LEU  A 319 ( 0.6A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
SER  A 355 ( 0.0A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
PHE  A 372 (-1.3A)
0.73A 1xotB-3sl5A:
50.9
1xotB-3sl5A:
84.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2H42_A_VIAA901_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 TYR A 159
HIS A 160
PHE A 340
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.50A 2h42A-3sl5A:
36.2
2h42A-3sl5A:
29.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2H42_C_VIAC903_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 TYR A 159
LEU A 319
PHE A 340
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
LEU  A 319 ( 0.6A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.43A 2h42C-3sl5A:
35.9
2h42C-3sl5A:
29.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Q0J_B_BEZB500_0
(QUINOLONE SIGNAL
RESPONSE PROTEIN)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 ASP A 201
HIS A 200
ASP A 318
LEU A 319
HIS A 164
ASP  A 201 ( 0.5A)
HIS  A 200 (-1.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
HIS  A 164 (-1.0A)
1.25A 2q0jB-3sl5A:
undetectable
2q0jB-3sl5A:
20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
8 / 12 TYR A 159
HIS A 160
LEU A 319
ILE A 336
GLU A 339
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
LEU  A 319 ( 0.6A)
ILE  A 336 ( 0.4A)
GLU  A 339 ( 0.5A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
1.01A 2weyA-3sl5A:
37.9
2weyA-3sl5A:
27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
8 / 12 TYR A 159
HIS A 160
LEU A 319
ILE A 336
GLU A 339
PHE A 340
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
LEU  A 319 ( 0.6A)
ILE  A 336 ( 0.4A)
GLU  A 339 ( 0.5A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.83A 2weyA-3sl5A:
37.9
2weyA-3sl5A:
27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
4 / 8 ILE A 336
MET A 357
GLN A 369
PHE A 372
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.86A 2weyB-3sl5A:
37.4
2weyB-3sl5A:
27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
4 / 8 ILE A 336
PHE A 340
GLN A 369
PHE A 372
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.54A 2weyB-3sl5A:
37.4
2weyB-3sl5A:
27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YJA_B_ESTB1550_1
(ESTROGEN RECEPTOR)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 ALA A 317
LEU A 175
LEU A 176
MET A 122
ILE A 125
ALA  A 317 ( 0.0A)
LEU  A 175 ( 0.6A)
LEU  A 176 ( 0.6A)
MET  A 122 ( 0.0A)
ILE  A 125 ( 0.6A)
1.14A 2yjaB-3sl5A:
undetectable
2yjaB-3sl5A:
22.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
6 / 12 TYR A 159
HIS A 160
LEU A 319
PHE A 340
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
LEU  A 319 ( 0.6A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.55A 3b2rA-3sl5A:
31.7
3b2rA-3sl5A:
29.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 TYR A 159
HIS A 160
LEU A 319
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
LEU  A 319 ( 0.6A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.45A 3b2rB-3sl5A:
31.6
3b2rB-3sl5A:
29.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CZV_A_AZMA263_1
(CARBONIC ANHYDRASE
13)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 HIS A 164
HIS A 200
PHE A 372
THR A 271
VAL A 377
HIS  A 164 (-1.0A)
HIS  A 200 (-1.0A)
PHE  A 372 (-1.3A)
THR  A 271 ( 0.8A)
VAL  A 377 ( 0.6A)
1.20A 3czvA-3sl5A:
undetectable
3czvB-3sl5A:
undetectable
3czvA-3sl5A:
20.73
3czvB-3sl5A:
20.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_A_ROFA901_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
10 / 12 TYR A 159
HIS A 160
ASN A 321
PRO A 322
TYR A 329
TRP A 332
THR A 333
ILE A 336
MET A 357
SER A 368
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
ASN  A 321 (-0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
SER  A 368 (-0.0A)
0.52A 3g4lA-3sl5A:
53.4
3g4lA-3sl5A:
98.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_A_ROFA901_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
11 / 12 TYR A 159
HIS A 160
MET A 273
ASN A 321
PRO A 322
TYR A 329
TRP A 332
THR A 333
ILE A 336
SER A 368
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASN  A 321 (-0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
SER  A 368 (-0.0A)
PHE  A 372 (-1.3A)
0.44A 3g4lA-3sl5A:
53.4
3g4lA-3sl5A:
98.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_A_ROFA901_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
3 / 3 ASP A 318
LEU A 319
GLN A 369
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
GLN  A 369 (-0.6A)
0.34A 3g4lA-3sl5A:
53.4
3g4lA-3sl5A:
98.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_B_ROFB902_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
PRO A 322
TRP A 332
THR A 333
ILE A 336
MET A 337
MET A 357
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
MET  A 357 (-0.0A)
PHE  A 372 (-1.3A)
0.53A 3g4lB-3sl5A:
52.8
3g4lB-3sl5A:
98.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_C_ROFC903_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
ASN A 321
PRO A 322
TYR A 329
TRP A 332
THR A 333
ILE A 336
MET A 357
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
ASN  A 321 (-0.6A)
PRO  A 322 (-1.1A)
TYR  A 329 (-1.3A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
0.46A 3g4lC-3sl5A:
53.0
3g4lC-3sl5A:
98.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_C_ROFC903_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
3 / 3 SER A 368
GLN A 369
PHE A 372
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.45A 3g4lC-3sl5A:
53.0
3g4lC-3sl5A:
98.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G4L_D_ROFD904_0
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
12 / 12 TYR A 159
HIS A 160
MET A 273
ASP A 318
LEU A 319
PRO A 322
TRP A 332
THR A 333
ILE A 336
MET A 337
SER A 368
GLN A 369
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 273 (-0.0A)
ASP  A 318 (-0.5A)
LEU  A 319 ( 0.6A)
PRO  A 322 (-1.1A)
TRP  A 332 ( 0.5A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 337 ( 0.0A)
SER  A 368 (-0.0A)
GLN  A 369 (-0.6A)
0.33A 3g4lD-3sl5A:
52.9
3g4lD-3sl5A:
98.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IA4_C_MTXC164_1
(DIHYDROFOLATE
REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 ALA A 193
LEU A 260
PHE A 195
ILE A 248
LEU A 241
ALA  A 193 ( 0.0A)
LEU  A 260 ( 0.6A)
PHE  A 195 ( 1.3A)
ILE  A 248 ( 0.7A)
LEU  A 241 ( 0.6A)
1.31A 3ia4C-3sl5A:
undetectable
3ia4C-3sl5A:
16.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
8 / 9 TYR A 159
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
ILE A 376
TYR  A 159 (-1.3A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
ILE  A 376 (-0.6A)
0.53A 3iakA-3sl5A:
51.9
3iakA-3sl5A:
94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
8 / 9 TYR A 159
MET A 273
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
MET  A 273 (-0.0A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.73A 3iakA-3sl5A:
51.9
3iakA-3sl5A:
94.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JWQ_A_VIAA901_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
CATALYTIC DOMAIN,
CONE CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
SUBUNIT ALPHA
CHIMERA)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 9 TYR A 159
HIS A 160
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
1.01A 3jwqA-3sl5A:
39.2
3jwqA-3sl5A:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JWQ_B_VIAB901_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
CATALYTIC DOMAIN,
CONE CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
SUBUNIT ALPHA
CHIMERA)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 TYR A 159
HIS A 160
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.94A 3jwqB-3sl5A:
39.0
3jwqC-3sl5A:
39.2
3jwqB-3sl5A:
28.41
3jwqC-3sl5A:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JWQ_C_VIAC901_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
CATALYTIC DOMAIN,
CONE CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
SUBUNIT ALPHA
CHIMERA)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 7 TYR A 159
HIS A 160
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.91A 3jwqC-3sl5A:
39.2
3jwqC-3sl5A:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3JWQ_D_VIAD901_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
CATALYTIC DOMAIN,
CONE CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
SUBUNIT ALPHA
CHIMERA)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
6 / 11 TYR A 159
HIS A 160
PHE A 340
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
1.01A 3jwqA-3sl5A:
39.2
3jwqD-3sl5A:
38.8
3jwqA-3sl5A:
28.41
3jwqD-3sl5A:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OLS_B_ESTB600_1
(ESTROGEN RECEPTOR
BETA)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 MET A 286
LEU A 283
LEU A 279
ILE A 307
LEU A 300
MET  A 286 ( 0.0A)
LEU  A 283 ( 0.6A)
LEU  A 279 ( 0.6A)
ILE  A 307 ( 0.4A)
LEU  A 300 ( 0.6A)
1.18A 3olsB-3sl5A:
undetectable
3olsB-3sl5A:
20.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TVX_A_PNXA902_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4A)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
9 / 9 TYR A 159
LEU A 319
ASN A 321
PRO A 322
THR A 333
ILE A 336
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
LEU  A 319 ( 0.6A)
ASN  A 321 (-0.6A)
PRO  A 322 (-1.1A)
THR  A 333 ( 0.8A)
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.46A 3tvxA-3sl5A:
51.5
3tvxA-3sl5A:
85.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TVX_B_PNXB902_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4A)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
7 / 7 TYR A 159
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.52A 3tvxB-3sl5A:
51.6
3tvxB-3sl5A:
85.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AX8_A_SAMA1474_1
(WBDD)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
4 / 6 TYR A 223
ASP A 203
GLU A 243
LEU A 234
TYR  A 223 ( 1.3A)
ASP  A 203 ( 0.6A)
GLU  A 243 ( 0.5A)
LEU  A 234 ( 0.6A)
1.16A 4ax8A-3sl5A:
undetectable
4ax8A-3sl5A:
21.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XI3_D_29SD601_1
(ESTROGEN RECEPTOR)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 ALA A 317
TRP A 102
LEU A 175
LEU A 176
MET A 122
ALA  A 317 ( 0.0A)
TRP  A 102 ( 0.5A)
LEU  A 175 ( 0.6A)
LEU  A 176 ( 0.6A)
MET  A 122 ( 0.0A)
1.15A 4xi3D-3sl5A:
undetectable
4xi3D-3sl5A:
20.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XK8_A_PQNA844_1
(PHOTOSYSTEM I P700
CHLOROPHYLL A
APOPROTEIN A1)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
4 / 7 MET A 122
PHE A 126
ALA A 192
LEU A 191
MET  A 122 ( 0.0A)
PHE  A 126 ( 1.3A)
ALA  A 192 ( 0.0A)
LEU  A 191 ( 0.6A)
1.12A 4xk8A-3sl5A:
undetectable
4xk8A-3sl5A:
18.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4YHA_B_MZMB303_1
(ALPHA-CARBONIC
ANHYDRASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 10 ASP A 305
VAL A 309
LEU A 181
THR A 178
ALA A 180
ASP  A 305 ( 0.5A)
VAL  A 309 ( 0.6A)
LEU  A 181 ( 0.6A)
THR  A 178 ( 0.8A)
ALA  A 180 ( 0.0A)
1.37A 4yhaB-3sl5A:
undetectable
4yhaB-3sl5A:
23.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5F8Y_A_X6XA202_1
(GALNAC/GAL-SPECIFIC
LECTIN)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 8 GLU A 339
VAL A 157
HIS A 160
ASP A 201
HIS A 233
GLU  A 339 ( 0.5A)
VAL  A 157 ( 0.6A)
HIS  A 160 ( 1.0A)
ASP  A 201 ( 0.5A)
HIS  A 233 ( 1.0A)
1.31A 5f8yA-3sl5A:
undetectable
5f8yA-3sl5A:
16.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5F8Y_B_X6XB201_1
(GALNAC/GAL-SPECIFIC
LECTIN)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 8 GLU A 339
VAL A 157
HIS A 160
ASP A 201
HIS A 233
GLU  A 339 ( 0.5A)
VAL  A 157 ( 0.6A)
HIS  A 160 ( 1.0A)
ASP  A 201 ( 0.5A)
HIS  A 233 ( 1.0A)
1.34A 5f8yB-3sl5A:
undetectable
5f8yB-3sl5A:
16.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G08_A_Z80A1187_1
(FREQUENIN 2)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
4 / 6 ILE A 336
PHE A 341
THR A 409
TRP A 405
ILE  A 336 ( 0.4A)
PHE  A 341 ( 1.3A)
THR  A 409 ( 0.8A)
TRP  A 405 ( 0.5A)
1.14A 5g08A-3sl5A:
undetectable
5g08A-3sl5A:
19.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_A_RAUA400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 VAL A 169
LEU A 149
MET A 122
SER A 197
GLY A 237
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
MET  A 122 ( 0.0A)
SER  A 197 ( 0.0A)
GLY  A 237 ( 0.0A)
1.49A 5g6sA-3sl5A:
0.7
5g6sG-3sl5A:
0.0
5g6sA-3sl5A:
22.85
5g6sG-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_A_RAUA400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 VAL A 169
LEU A 149
TYR A 145
MET A 122
GLY A 237
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
TYR  A 145 ( 1.3A)
MET  A 122 ( 0.0A)
GLY  A 237 ( 0.0A)
1.25A 5g6sA-3sl5A:
0.7
5g6sG-3sl5A:
0.0
5g6sA-3sl5A:
22.85
5g6sG-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_B_RAUB400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 VAL A 169
LEU A 149
TYR A 145
MET A 122
GLY A 237
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
TYR  A 145 ( 1.3A)
MET  A 122 ( 0.0A)
GLY  A 237 ( 0.0A)
1.23A 5g6sB-3sl5A:
undetectable
5g6sC-3sl5A:
0.7
5g6sB-3sl5A:
22.85
5g6sC-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_C_RAUC400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 MET A 122
GLY A 237
VAL A 169
LEU A 149
TYR A 145
MET  A 122 ( 0.0A)
GLY  A 237 ( 0.0A)
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
TYR  A 145 ( 1.3A)
1.25A 5g6sB-3sl5A:
undetectable
5g6sC-3sl5A:
undetectable
5g6sB-3sl5A:
22.85
5g6sC-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_C_RAUC400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 MET A 122
SER A 197
GLY A 237
VAL A 169
LEU A 149
MET  A 122 ( 0.0A)
SER  A 197 ( 0.0A)
GLY  A 237 ( 0.0A)
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
1.49A 5g6sB-3sl5A:
undetectable
5g6sC-3sl5A:
undetectable
5g6sB-3sl5A:
22.85
5g6sC-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_D_RAUD400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 10 VAL A 169
LEU A 149
TYR A 145
MET A 122
GLY A 237
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
TYR  A 145 ( 1.3A)
MET  A 122 ( 0.0A)
GLY  A 237 ( 0.0A)
1.24A 5g6sD-3sl5A:
0.7
5g6sF-3sl5A:
0.0
5g6sD-3sl5A:
22.85
5g6sF-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5G6S_E_RAUE400_1
(IMINE REDUCTASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 11 VAL A 169
LEU A 149
TYR A 145
MET A 122
GLY A 237
VAL  A 169 ( 0.6A)
LEU  A 149 ( 0.6A)
TYR  A 145 ( 1.3A)
MET  A 122 ( 0.0A)
GLY  A 237 ( 0.0A)
1.24A 5g6sE-3sl5A:
0.7
5g6sH-3sl5A:
undetectable
5g6sE-3sl5A:
22.85
5g6sH-3sl5A:
22.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5GTR_A_ESTA601_1
(ESTROGEN RECEPTOR)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
5 / 12 ALA A 317
LEU A 175
LEU A 176
MET A 122
ILE A 125
ALA  A 317 ( 0.0A)
LEU  A 175 ( 0.6A)
LEU  A 176 ( 0.6A)
MET  A 122 ( 0.0A)
ILE  A 125 ( 0.6A)
1.08A 5gtrA-3sl5A:
3.2
5gtrA-3sl5A:
21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OEX_A_CUA604_0
(THIOCYANATE
DEHYDROGENASE)
3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D

(Homo
sapiens)
3 / 3 HIS A 164
HIS A 160
HIS A 204
HIS  A 164 (-1.0A)
HIS  A 160 ( 1.0A)
HIS  A 204 ( 1.0A)
1.00A 5oexA-3sl5A:
undetectable
5oexA-3sl5A:
22.61